Upstream Will Use Genpathway's ChIP Assays to Validate Cancer Biomarkers | GenomeWeb
NEW YORK (GenomeWeb News) — Upstream Biosciences has hired Genpathway to use its chromatin immunoprecipitation assays in its cancer biomarker-validation studies, Upstream Bio said today.
 
Genpathway will use its assays to “help elucidate critical parameters involving specific gene transcription factors and pathways” and provide “critical information for the next phase of Upstream's program to validate its first two cancer biomarkers and drug response assay,” according to Upstream.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.